Thermo Fisher Scientific (NYSE:TMO) Reaches New 12-Month High - Still a Buy?

Key Points

• Thermo Fisher Scientific reached a new 52-week high of $683.32, with shares recently trading near $680. The stock’s average analyst rating is “Moderate Buy,” although the consensus price target of $628.78 is below the current price.
• The company reported strong quarterly results, posting EPS of $6.03 versus estimates of $5.71 and revenue of $11.99 billion, up 10.5% year over year. Management provided fiscal 2026 EPS guidance of $24.93–$25.33.
• Thermo Fisher declared a quarterly dividend of $0.47 per share, representing a 0.3% yield, while insiders sold approximately $44.1 million of shares over the past three months. Institutional investors continue to own a substantial 89.23% of the stock.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) hit a new 52-week high on Wednesday. The company traded as high as $683.32 and last traded at $680.0990, with a volume of 711022 shares changing hands. The stock had previously closed at $679.61.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent research reports. HSBC upgraded Thermo Fisher Scientific from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 1st. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Saturday, September 12th. Jefferies Financial Group restated a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $628.78.

Thermo Fisher Scientific Trading Up 0.1%

The stock has a fifty day simple moving average of $612.25 and a 200 day simple moving average of $531.12. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a market cap of $251.43 billion, a P/E ratio of 36.57, a price-to-earnings-growth ratio of 2.84 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same period last year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Several large investors have recently added to or reduced their stakes in the business. Tsfg LLC boosted its stake in shares of Thermo Fisher Scientific by 20.4% during the 2nd quarter. Tsfg LLC now owns 112 shares of the medical research company's stock worth $56,000 after acquiring an additional 19 shares during the last quarter. Renasant Bank lifted its position in Thermo Fisher Scientific by 1.0% during the second quarter. Renasant Bank now owns 1,934 shares of the medical research company's stock valued at $970,000 after purchasing an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. grew its holdings in Thermo Fisher Scientific by 5.4% during the first quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company's stock valued at $212,000 after purchasing an additional 22 shares during the period. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after buying an additional 22 shares in the last quarter. Finally, Chesapeake Wealth Management raised its stake in shares of Thermo Fisher Scientific by 0.6% in the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company's stock worth $1,868,000 after buying an additional 22 shares during the period. 89.23% of the stock is currently owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.